Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 5:16:39-46.
doi: 10.2147/CCID.S378985. eCollection 2023.

Serum miR-342-3p Acts as a Biomarker for Systemic Lupus Erythematosus and Participates in the Disease Progression

Min You  1 , Long Zhang  1 , Junxiao Ding  1
Affiliations

Serum miR-342-3p Acts as a Biomarker for Systemic Lupus Erythematosus and Participates in the Disease Progression

Min You et al. Clin Cosmet Investig Dermatol. .

Abstract

Purpose: The aim of this study was to investigate the diagnostic ability and prognostic value of miR-342-3p in SLE patients by detecting the expression level of serum miR-342-3p in SLE patients.

Patients and methods: The expression level of serum miR-342-3p in all subjects was determined by qRT-PCR technology, and the correlation of miR-342-3p with SLEDAI scores was evaluated using Spearman correlation coefficient. The diagnostic value of miR-342-3p in SLE was assessed using ROC curve. The prognostic value of miR-342-3p in SLE patients was analyzed by Kaplan-Meier survival curve and multivariate COX regression.

Results: The qRT-PCR results showed that the expression level of serum miR-342-3p in SLE patients was significantly lower than that in healthy controls (P < 0.001). Serum miR-342-3p expression level was negatively correlated with SLEDAI scores (r = - 0.810, P < 0.001). The ROC curve suggested that serum miR-342-3p expression level was discriminative between SLE patients and healthy controls. Survival analysis results indicated that SLE patients with low serum miR-342-3p expression had a higher probability of poor prognosis of SLE (Log rank P = 0.003).

Conclusion: The expression level of serum miR-342-3p was valuable in the diagnosis of SLE. Meanwhile, the low expression level of serum miR-342-3p was associated with the poor prognosis of SLE.

Keywords: diagnosis; miR-342-3p; prognosis; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Serum miR-342-3p expression level in all participants in this study. The expression level of miR-342-3p in SLE patients was significantly decreased in comparison with the healthy controls. ***P < 0.001.
Figure 2
Figure 2
The correlation of serum miR-342-3p level with SLEDAI scores in SLE patients. Serum miR-342-3p levels were negatively correlated with SLEDAI scores (r = - 0.810, P < 0.001) in SLE patients.
Figure 3
Figure 3
An ROC curve was established to evaluate the diagnostic value of serum miR-342-3p in SLE. MiR-342-3p has high diagnostic capacity as a biomarker for SLE, with an AUC value of 0.870, a sensitivity of 70.0%, and a specificity of 90.6%.
Figure 4
Figure 4
Kaplan–Meier curves of survival probability of patients with SLE stratified by the serum miR-342-3p expression levels. Patients with low serum miR-342-3p expression levels had shorter event free survival probability than that with high serum miR-342-3p levels (Log Rank P = 0.003).
See this image and copyright information in PMC

References

    1. Hanly JG, Su L, Urowitz MB, et al. A longitudinal analysis of outcomes of lupus nephritis in an international inception cohort using a multistate model approach. Arthritis Rheumatol. 2016;68(8):1932–1944. doi:10.1002/art.39674 - DOI - PMC - PubMed
    1. Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332–2343. doi:10.1016/S0140-6736(19)30237-5 - DOI - PubMed
    1. Liu S, Cheng Y, Xie Z, et al. A conscious resting state fMRI study in SLE patients without major neuropsychiatric manifestations. Front Psychiatry. 2018;9:677. doi:10.3389/fpsyt.2018.00677 - DOI - PMC - PubMed
    1. Flynn A, Gilhooley E, O’Shea F, Wynne B. The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus. Clin Rheumatol. 2018;37(3):817–818. doi:10.1007/s10067-018-3999-0 - DOI - PubMed
    1. Satish S, Deka P, Shetty MS. A clinico-pathological study of lupus nephritis based on the international society of nephrology-renal pathology society 2003 classification system. J Lab Physicians. 2017;9(3):149–155. doi:10.4103/JLP.JLP_44_16 - DOI - PMC - PubMed